Ipid Management News Today

Researchers have identified significant and specific variations in the microbial universe of the small intestine in overweight or obese adults compared with normal-weight peers.

Study finds slightly higher risk in children at 10 years, but experts say this shouldn't change current supplementation recommendations.

The experimental siRNA agent led to prolonged Lp(a) reduction of more than 90%, extended data from the phase 1 trial show, supporting the move to phases 2 and 3 trials.

In patients with severe hypertriglyceridemia who are at risk for acute pancreatitis, the drug brought about triglyceride reductions of more than 50% in the phase 2 SHASTA-2 study.

A drug targeting mRNA essential for APO C-III production provided a 50% reduction in triglycerides in BRIDGE-TIMI 73a, the largest ever observed in a controlled trial.

ApoA1 infusions in acute MI did not significantly reduce the composite endpoint in the AEGIS-II trial. However, an exploratory analysis suggested benefit at higher LDL levels.

New analysis of the REDUCE-IT trial suggested benefit of icosapent ethyl doesn't vary by Lp(a) level and confirmed risk for Lp(a) with high triglycerides but not cholesterol.

A phase 1 gene editing trial in patients with heterozygous familial hypercholesterolemia and atherosclerotic CVD was paused after abnormal lab results were seen.

Meal intake reduced the tone of the lower esophageal sphincter and increased the number of transient lower esophageal sphincter relaxations.

Physicians should pay attention to patients with higher risks for not receiving treatment, such as women and patients with normal BMI, said researchers.